IL-23 Inhibition in Ankylosing Spondylitis: Where Did It Go Wrong?

Area of Science:

• Immunology
• Rheumatology
• Inflammatory Diseases

Background:

• Axial spondyloarthritis (axSpA) is a chronic inflammatory arthritis linked to psoriatic arthritis and psoriasis.
• Tumor necrosis factor (TNF), IL-17A, and IL-17F are key cytokines in axSpA pathobiology, with targeted inhibition showing therapeutic benefits.
• Interleukin-23 (IL-23) drives Th17 cells, which produce IL-17, and is effective in psoriasis, but its role in axSpA is less clear.

Purpose of the Study:

• To re-examine the rationale for IL-23's involvement in axSpA.
• To discuss current understanding of axSpA pathobiology and the IL-23/IL-17 axis.
• To identify lessons for translating biological insights into clinical therapies for axSpA.

Main Methods:

• Viewpoint article synthesizing existing research and clinical observations.
• Discussion of the IL-23/IL-17 pathway in the context of spondyloarthritis.
• Analysis of therapeutic outcomes and pathobiological mechanisms.

Main Results:

• While IL-23 inhibition is effective in psoriasis, it has not shown clinical efficacy in axSpA.
• The IL-23/IL-17 axis is crucial in axSpA, but its precise role and therapeutic targeting require further investigation.
• Understanding the nuances of this pathway is critical for developing new treatments.

Conclusions:

• Despite clinical trial outcomes, a role for IL-23 in axSpA pathobiology warrants continued exploration.
• Further research into the IL-23/IL-17 axis may reveal specific therapeutic strategies for axSpA.
• Translating complex immunological insights into effective axSpA treatments remains a key challenge.